🇺🇸 FDA
Pipeline program

Bone marrow mesenchymal stem cells autologous

CeTMMo/EM/2010

Phase 2 other completed

Quick answer

Bone marrow mesenchymal stem cells autologous for Multiple Sclerosis is a Phase 2 program (other) at Design Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Design Therapeutics
Indication
Multiple Sclerosis
Phase
Phase 2
Modality
other
Status
completed

Clinical trials